1. Membrane Transporter/Ion Channel
  2. CFTR

KM11060 

Cat. No.: HY-19970
Handling Instructions

KM11060 is a novel corrector of the F508del-CFTR trafficking defect.

For research use only. We do not sell to patients.
KM11060 Chemical Structure

KM11060 Chemical Structure

CAS No. : 774549-97-2

Size Price Stock Quantity
10 mM * 1 mL in DMSO USD 106 In-stock
10 mg USD 96 In-stock
50 mg USD 384 In-stock
100 mg USD 672 In-stock
200 mg   Get quote  
500 mg   Get quote  

* Please select Quantity before adding items.

Customer Review

    KM11060 purchased from MCE. Usage Cited in: Patent. US 20150328217 A1.

    CFTR correctors (Compounds A to F) promote the rescue of R98H mutant of alpha-sarcoglycan in HEK293 cell model. Alpha-sarcoglycan (α-SG) protein level has been determined by western blot (a representative experiment is shown in the top panel) on total protein content purified from cells expressing the R98H mutant treated with either CFTR correctors (compound A, B, C, D, E and F as indicated), MG132 (proteasome inhibitor) used as positive control, or correctors vehicle (DMSO) used as negative con

    Featured Recommendations

    Related Screening Libraries:

    Related Small Molecules:

    • Biological Activity

    • Protocol

    • Technical Information

    • References

    Description

    KM11060 is a novel corrector of the F508del-CFTR trafficking defect. Target: CFTR in vitro: Small-molecule correctors such as KM11060 may serve as useful pharmacological tools in studies of the F508del-CFTR processing defect and in the development of cystic fibrosis therapeutics. KM11060 rescues F508del-CFTR trafficking in cultured cells and native epithelial tissues. KM11060 partially corrects F508del-CFTR processing and increases surface expression to 75% of that observed in cells incubated at low temperature. Up to 50% of the F508del-CFTR in cells treated with KM11060 was complex-glycosylated, indicating passage through the Golgi. KM11060 as a promising compound for further development of CF therapeutics. [1] in vivo: In LPS-induced acute lung inflammation, blockade of PSGL-1 (P-selectin glycoprotein ligand-1) or P-selectin, antagonism of PAF by WEB2086, or correction of mutated CFTR trafficking by KM11060 could significantly increase plasma lipoxin A4 levels in F508del relevant to wildtype mice. [2]

    References
    Preparing Stock Solutions
    Concentration Volume Mass 1 mg 5 mg 10 mg
    1 mM 2.3678 mL 11.8391 mL 23.6782 mL
    5 mM 0.4736 mL 2.3678 mL 4.7356 mL
    10 mM 0.2368 mL 1.1839 mL 2.3678 mL
    Please refer to the solubility information to select the appropriate solvent.
    References
    Molecular Weight

    422.33

    Formula

    C₁₉H₁₇Cl₂N₃O₂S

    CAS No.

    774549-97-2

    Storage
    Powder -20°C 3 years
      4°C 2 years
    In solvent -80°C 6 months
      -20°C 1 month
    Shipping

    Room temperature in continental US; may vary elsewhere

    Solvent & Solubility

    10 mM in DMSO

    * "<1 mg/mL" means slightly soluble or insoluble. "≥" means soluble, but saturation unknown.

    Inquiry Online

    Your information is safe with us. * Required Fields.

    Product name

     

    Salutation

    Applicant name *

     

    Email address *

    Phone number *

     

    Organization name *

    Country *

     

    Requested quantity *

    Remarks

    Bulk Inquiry

    Inquiry Information

    Product Name:
    KM11060
    Cat. No.:
    HY-19970
    Quantity: